Vaccine approved amid surge in cases
Balance Sheet Risk Management
Financial Institutions | Kennett Square, PA
SummaryDespite COVID-19 vaccine developments and renewed stimulus bill hope, the major U.S. equity indices moved lower for the week as the continued rise in COVID-19 cases and the recent return of virus-related restrictions in many regions dampened investor sentiment and darkened the economic outlook.
Prior week summary
Despite positive COVID-19 vaccine developments and renewed stimulus bill hope, the major U.S. equity indices moved lower for the week as the continued rise in COVID-19 cases across the country and the recent return of virus-related restrictions in many regions dampened investor sentiment and darkened the economic outlook. As of Sunday evening, the U.S. tally of confirmed COVID-19 cases sits just above 16.2 million with over 108,000 individuals currently hospitalized with the disease. While state and local governments have implemented restrictions on activity and movement in recent weeks, cases continue to rise at an accelerated pace with the U.S. averaging over 209,000 cases per day and nearly 2,400 deaths per day over the last week. Notably, California, which recently imposed significant restrictions in many regions after ICU capacity dipped below 15% last weekend, saw a 47% week over week increase in the seven-day average daily case count. Separately, New York Governor Andrew Cuomo announced new restrictions on Friday which will see indoor dining in New York City suspended indefinitely, beginning Monday, after hospitalizations and positivity rates surpassed thresholds that triggered the restrictions. Detailing the new restrictions to reporters on Friday, Governor Cuomo highlighted the most severe tier-based restrictions saying, “If we don’t slow the spread and we overwhelm the hospital system — we get a red zone. Then, every restaurant goes to zero indoor, outdoor zero. That’s the worst-case scenario.”
As the virus surges across the country, market participants welcomed a Food and Drug Administration (FDA) panel’s recommendation that the Pfizer-BioNTech vaccine receives approval for emergency use on Thursday. As expected, the FDA authorized the new vaccine for emergency use on Friday, setting the stage for inoculations to begin next week. In a statement released announcing the Emergency Use Authorization (EUA), the FDA said, “The FDA has determined that Pfizer-BioNTech COVID-19 Vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that Pfizer-BioNTech COVID-19 Vaccine may be effective in preventing COVID-19,” and noted, “In making this determination, the FDA can assure the public and medical community that it has conducted a thorough evaluation of the available safety, effectiveness and manufacturing quality information.” On Sunday, Centers for Disease Control and Prevention Director Robert Redfield formally signed off on an advisory panel’s recommendation that advocated the use of the vaccine in the community. With all the necessary approvals in hand, distribution of the vaccine began in mass on Sunday with the first inoculations expected to take place on Monday.
After several weeks with little discourse on a COVID-19 relief package, a bipartisan group of lawmakers announced the outline for a $908B relief package that includes both liability protections for businesses against COVID-19-related claims and aid for state and local governments. The proposed bill notably excludes a second round of direct payments to individuals. Support for the package from the senior leaders of each party remains lukewarm with the possibility of a deal before year-end uncertain, but the bill is expected to be formally introduced on Monday. House Majority Leader Steny Hoyer expressed optimism about the deal’s near-term prospects on Sunday saying, “House Speaker Nancy Pelosi and I spent a lot of time on the phone together. And I am very hopeful that next week, we will be able to act on substantial relief,” and noted, “We need to get the essential done. We’ll have time to get stuff done that we didn’t include because we couldn’t get political agreement, we’ll have time to do that.”
In a light week for economic data releases, market participants received updates that largely pointed to a slowing U.S. recovery. Jobless claims jumped to 853,000 filings last week, a three-month high and far above the 716,000 filings seen the week prior. The largest increases were seen in states with recent surges in COVID-19 cases like California, Texas, Illinois, and New York. Continuing claims also ticked higher, with 5.76 million individuals continuing to receive unemployment benefits compared to 5.53 million individuals the week prior. The Consumer Price Index (CPI) indicated that prices increased 0.2% in November, above analyst calls for a 0.1% increase and October’s 0.0% reading. The pace of inflation remains stubbornly low with prices up 1.2% year over year as measured by the CPI.
The look forward
Market participants are gearing up for a busy week of economic data releases with updated figures on the Empire Manufacturing Index, the Philadelphia Fed Business Outlook Survey, industrial production, retail sales, jobless claims, and housing starts, among others, set for release. The FOMC holds its final policy meeting of the year on Tuesday and Wednesday.
Market implied policy path (Overnight indexed swap rates)
Chatham Hedging Advisors, LLC (CHA) is a subsidiary of Chatham Financial Corp. and provides hedge advisory, accounting and execution services related to swap transactions in the United States. CHA is registered with the Commodity Futures Trading Commission (CFTC) as a commodity trading advisor and is a member of the National Futures Association (NFA); however, neither the CFTC nor the NFA have passed upon the merits of participating in any advisory services offered by CHA. For further information, please visit chathamfinancial.com/legal-notices.
Transactions in over-the-counter derivatives (or “swaps”) have significant risks, including, but not limited to, substantial risk of loss. You should consult your own business, legal, tax and accounting advisers with respect to proposed swap transaction and you should refrain from entering into any swap transaction unless you have fully understood the terms and risks of the transaction, including the extent of your potential risk of loss. This material has been prepared by a sales or trading employee or agent of Chatham Hedging Advisors and could be deemed a solicitation for entering into a derivatives transaction. This material is not a research report prepared by Chatham Hedging Advisors. If you are not an experienced user of the derivatives markets, capable of making independent trading decisions, then you should not rely solely on this communication in making trading decisions. All rights reserved.20-0470
Our featured insights
Expert conversation with Matt Henry and Jackie Bowie
Matt Henry, Chatham's Managing Partner and CEO, sat down with Jackie Bowie, Managing Partner and Head of Europe. In this interview, Jackie discusses macro and micro economic issues and trends that the U.K. and Europe could be facing going into 2023 and 2024.
Why it’s not too late for interest rate swaps
Bob Newman writes for Bank Director and discusses why community and regional banks should consider using derivatives as a tool to manage interest rate risk.
Banks tightened and the market rallied: what’s going on?
The European Central Bank (ECB), Bank of England (BoE), and U.S. Federal Reserve (Fed) all raised their respective benchmark rates last week. The ECB raised rates by 50 basis points to a key rate of 2.5% on Thursday and signaled another 50-basis-point hike was coming at the next meeting in March....
Big NFP beat sends yields higher
In an eventful week in the financial markets, Treasury yields moved higher, and the major U.S. equity indices ended the week mixed as market participants reacted to a better-than-expected January employment report, solid fourth-quarter earnings releases, and the latest commentary from Fed Chair...
Hikes continue but signs of easing on the horizon?
On 2 February, the European Central Bank (ECB) voted for a further 0.50% interest rate increase in a move widely expected by markets following the hawkish stance of ECB policymakers at the prior meeting. Core inflation remained steady at 5.20%, supporting ECB President Christine Lagarde’s...
A year of Fed interest rate hikes
On Wednesday, February 1, 2023, the Federal Open Market Committee (FOMC) increased interest rates by 25 basis points for a target fed funds range of 450–475. This rate increase marks another decrease in size of these rate hikes, but it shows that the Fed continues applying pressure on inflation....
Back-to-Back Swap Program Benchmark Statistics Report
Our back-to-back swap benchmark report compares customer swap transactions across years, regions, and bank asset size. While your financial institution may not yet be using swaps to win more commercial loan business, you can still find value in reviewing this report.
GDP, PCE take steps in the right direction ahead of Fed meeting, China’s reopening leads to commodities shift
December metrics for GDP and inflation came in at promising levels, keeping market expectations consistent ahead of this week’s FOMC meeting. China’s reopening leads to increased economic activity, including increased demand for metals and oil, while natural gas struggles due to unexpectedly warm...